                         SEQUENCE LISTING

<110>  CRISPR Therapeutics AG
       Vertex Pharmaceuticals Incorporated
 
<120>  CRISPR-CAS9 MODIFIED CD34+ HUMAN HEMATOPOIETIC STEM AND 
       PROGENITOR CELLS AND USES THEREOF

<130>  C1542.70041WO00

<150>  US 62/594,689
<151>  2017-12-05

<150>  US 62/671,770
<151>  2018-05-15

<150>  US 62/734,431
<151>  2018-09-21

<150>  US 62/734,543
<151>  2018-09-21

<150>  US 62/664,023
<151>  2018-04-27

<160>  3     

<170>  PatentIn version 3.5

<210>  1
<211>  100
<212>  RNA
<213>  Artificial sequence

<220>
<223>  sgRNA

<400>  1
cuaacaguug cuuuuaucac guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc       60

cguuaucaac uugaaaaagu ggcaccgagu cggugcuuuu                            100


<210>  2
<211>  100
<212>  RNA
<213>  Artificial sequence

<220>
<223>  Modified sgRNA


<220>
<221>  modified_base
<222>  (1)..(3)
<223>  2'-O-methyl-phosphorothioate nucleotides

<220>
<221>  modified_base
<222>  (97)..(99)
<223>  2'-O-methyl-phosphorothioate nucleotides

<400>  2
cuaacaguug cuuuuaucac guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc       60

cguuaucaac uugaaaaagu ggcaccgagu cggugcuuuu                            100


<210>  3
<211>  23
<212>  DNA
<213>  Artificial sequence

<220>
<223>  Synthetic polynucleotide


<220>
<221>  misc_feature
<222>  (1)..(21)
<223>  n is a, c, g, or t

<400>  3
nnnnnnnnnn nnnnnnnnnn nrg                                               23


